

# Philip C Robinson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3906897/philip-c-robinson-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                    |                         |                |                 |
|--------------------|-------------------------|----------------|-----------------|
| 138<br>papers      | 4,534<br>citations      | 33<br>h-index  | 64<br>g-index   |
| 165<br>ext. papers | 6,386<br>ext. citations | 5.5<br>avg, IF | 6.31<br>L-index |

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 138 | Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 859-866 | 2.4  | 575       |
| 137 | Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , <b>2013</b> , 45, 730-8  | 36.3 | 551       |
| 136 | Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 686-691   | 9.5  | 252       |
| 135 | Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 930-942           | 2.4  | 210       |
| 134 | Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , <b>2015</b> , 6, 7146  | 17.4 | 164       |
| 133 | Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e250-e253   | 14.2 | 125       |
| 132 | Genetics of ankylosing spondylitis. <i>Molecular Immunology</i> , <b>2014</b> , 57, 2-11  | 4.3  | 96        |
| 131 | Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e653-e655  | 14.2 | 85        |
| 130 | Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 140-51  | 9.5  | 78        |
| 129 | COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies. <i>The Cochrane Library</i> , <b>2021</b> , 2021,  | 5.2  | 78        |
| 128 | Systematic review of the prevalence of gout and hyperuricaemia in Australia. <i>Internal Medicine Journal</i> , <b>2012</b> , 42, 997-1007  | 1.6  | 69        |
| 127 | Sonography of common tendon injuries. <i>American Journal of Roentgenology</i> , <b>2009</b> , 193, 607-18  | 5.4  | 69        |
| 126 | The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 293-294  | 8.1  | 64        |
| 125 | ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1627-9   | 2.4  | 63        |
| 124 | An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1702-7   | 4.1  | 62        |
| 123 | Imaging of Muscle Injuries in Sports Medicine: Sports Imaging Series. <i>Radiology</i> , <b>2017</b> , 282, 646-663   | 20.5 | 61        |
| 122 | Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 162-4  | 2.4  | 59        |

|     |  |     |    |
|-----|--|-----|----|
| 121 | Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. <i>Rheumatology</i> , <b>2013</b> , 52, 118-26  | 3.9 | 58 |
| 120 | Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 28   | 5.7 | 57 |
| 119 | Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1386-1388   | 2.4 | 56 |
| 118 | Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. <i>Maturitas</i> , <b>2014</b> , 78, 245-51  | 5   | 53 |
| 117 | The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. <i>Med</i> , <b>2020</b> , 1, 90-102  | 2.7 | 51 |
| 116 | Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1137-1146   | 2.4 | 49 |
| 115 | Impingement syndromes of the ankle. <i>European Radiology</i> , <b>2007</b> , 17, 3056-65  | 8   | 48 |
| 114 | Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Mulhearn. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , | 2.4 | 46 |
| 113 | Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1592-1600  | 2.4 | 45 |
| 112 | Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 659-666   | 5.1 | 40 |
| 111 | Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 427-434  | 4.7 | 39 |
| 110 | The genetics of ankylosing spondylitis and axial spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 539-53   | 2.4 | 38 |
| 109 | Gout - An update of aetiology, genetics, co-morbidities and management. <i>Maturitas</i> , <b>2018</b> , 118, 67-73  | 5   | 38 |
| 108 | Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , <b>2021</b> , 7,   | 5.9 | 36 |
| 107 | The window of opportunity: a relevant concept for axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 109   | 5.7 | 34 |
| 106 | Conventional 3-T MRI and 1.5-T MR arthrography of femoroacetabular impingement. <i>American Journal of Roentgenology</i> , <b>2012</b> , 199, 509-15   | 5.4 | 34 |
| 105 | SAPHO and CRMO: The Value of Imaging. <i>Seminars in Musculoskeletal Radiology</i> , <b>2018</b> , 22, 207-224   | 1.8 | 33 |
| 104 | Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals. <i>Journal of Clinical Rheumatology</i> , <b>2010</b> , 16, 267-73                                       | 1.1 | 32 |

|     |   |      |    |
|-----|---|------|----|
| 103 | Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. <i>Current Opinion in Rheumatology</i> , <b>2020</b> , 32, 434-440  | 5.3  | 32 |
| 102 | : hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 734-736  | 2.4  | 32 |
| 101 | <i>Rothia aeria</i> as a cause of sepsis in a native joint. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 2648-50   | 9.7  | 31 |
| 100 | Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 374-380                                  | 8.5  | 29 |
| 99  | Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis. <i>Rheumatology</i> , <b>2015</b> , 54, 1549-56  | 3.9  | 28 |
| 98  | Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 771-778   | 4.1  | 28 |
| 97  | Insight into rheumatological cause and effect through the use of Mendelian randomization. <i>Nature Reviews Rheumatology</i> , <b>2016</b> , 12, 486-96   | 8.1  | 28 |
| 96  | The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward. <i>Current Rheumatology Reports</i> , <b>2015</b> , 17, 62   | 4.9  | 27 |
| 95  | The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis. <i>Genes and Immunity</i> , <b>2016</b> , 17, 46-51   | 4.4  | 27 |
| 94  | The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2015</b> , 29, 202-12   | 5.3  | 26 |
| 93  | Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 317  | 4.9  | 26 |
| 92  | Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. <i>Genes and Immunity</i> , <b>2015</b> , 16, 35-42  | 4.4  | 26 |
| 91  | A qualitative and quantitative analysis of the characteristics of gout patient education resources. <i>Clinical Rheumatology</i> , <b>2013</b> , 32, 771-8  | 3.9  | 25 |
| 90  | Do MRI and ultrasound of the anterior pelvis correlate with, or predict, young football players's clinical findings? A 4-year prospective study of elite academy soccer players. <i>British Journal of Sports Medicine</i> , <b>2015</b> , 49, 176-82 | 10.3 | 25 |
| 89  | Glossary of terms for musculoskeletal radiology. <i>Skeletal Radiology</i> , <b>2020</b> , 49, 1-33   | 2.7  | 24 |
| 88  | Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 779-784   | 2.3  | 21 |
| 87  | Advances in pharmacotherapy for the treatment of gout. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 533-46  | 4    | 21 |
| 86  | Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease. <i>Npj Genomic Medicine</i> , <b>2016</b> , 1, 16008  | 6.2  | 21 |

|    |   |      |    |
|----|---|------|----|
| 85 | Axial spondyloarthritis: concept, construct, classification and implications for therapy. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 109-118  | 8.1  | 21 |
| 84 | Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci <b>2020</b> , 61, 3   |      | 20 |
| 83 | SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 269-271   | 2.4  | 20 |
| 82 | Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 165-177  | 4.4  | 18 |
| 81 | Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1185-1204   | 5.1  | 18 |
| 80 | Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2129639                                 | 10.4 | 17 |
| 79 | COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies <b>2021</b> , 9,   |      | 17 |
| 78 | Shear-Wave Elastography of Benign versus Malignant Musculoskeletal Soft-Tissue Masses: Comparison with Conventional US and MRI. <i>Radiology</i> , <b>2019</b> , 290, 410-417   | 20.5 | 17 |
| 77 | The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , <b>2021</b> , 60, 353-358   | 3.9  | 17 |
| 76 | Genetic diagnostic profiling in axial spondyloarthritis: a real world study. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 229-233  | 2.2  | 16 |
| 75 | Divergent effects of acute versus chronic glucocorticoids in COVID-19. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e168-e170   | 14.2 | 15 |
| 74 | ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2092-5                                    | 2.4  | 14 |
| 73 | Febuxostat for the treatment of hyperuricaemia in gout. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1289-1299  | 4    | 14 |
| 72 | Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2021</b> , 35, 101657  | 5.3  | 13 |
| 71 | ERAP1 biology and assessment in Ankylosing Spondylitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1816   | 11.5 | 12 |
| 70 | Imaging Athletic Groin Pain. <i>Radiologic Clinics of North America</i> , <b>2016</b> , 54, 865-73  | 2.3  | 12 |
| 69 | Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department. <i>Microbial Drug Resistance</i> , <b>2014</b> , 20, 561-7   | 2.9  | 11 |
| 68 | Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e855-e864 | 14.2 | 11 |

|    |   |      |    |
|----|---|------|----|
| 67 | Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 333-340   | 3.5  | 11 |
| 66 | Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e707-e714  | 14.2 | 11 |
| 65 | Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1091-1093  | 2.4  | 10 |
| 64 | Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1053-1059  | 4.1  | 10 |
| 63 | Lesinurad for the treatment of hyperuricaemia in people with gout. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1875-1881   | 4    | 9  |
| 62 | Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). <i>International Journal of Rheumatic Diseases</i> , <b>2014</b> , 17, 548-56   | 2.3  | 9  |
| 61 | Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e71-e82   | 14.2 | 9  |
| 60 | COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.. <i>Nature Reviews Rheumatology</i> , <b>2022</b> ,  | 8.1  | 9  |
| 59 | COVID-19 therapeutics: Challenges and directions for the future.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119, e2119893119   | 11.5 | 9  |
| 58 | The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 697-704  | 4.1  | 8  |
| 57 | MR Imaging of Impingement and Entrapment Syndromes of the Foot and Ankle. <i>Magnetic Resonance Imaging Clinics of North America</i> , <b>2017</b> , 25, 145-158  | 1.6  | 8  |
| 56 | Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 111-116   | 5.3  | 8  |
| 55 | Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , <b>2021</b> , 24, 733-745  | 2.3  | 8  |
| 54 | EVOLVE: The Australian Rheumatology Association's Top five list of investigations and interventions doctors and patients should question. <i>Internal Medicine Journal</i> , <b>2018</b> , 48, 135-143  | 1.6  | 8  |
| 53 | Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2017</b> , 61, 58-69   | 1.7  | 7  |
| 52 | Response to: Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by Gyffi. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,   | 2.4  | 7  |
| 51 | COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a | 2.4  | 6  |
| 50 | Waiting for JAK inhibitor safety data.. <i>RMD Open</i> , <b>2022</b> , 8, real-world district general hospital experiences by Khan. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,  | 5.9  | 6  |



|    |   |      |   |
|----|---|------|---|
| 49 | Role of genetics in infection-associated arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2015</b> , 29, 213-25   | 5.3  | 5 |
| 48 | Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. <i>Internal Medicine Journal</i> , <b>2015</b> , 45, 127-33  | 1.6  | 5 |
| 47 | Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S85-S88  | 1.7  | 5 |
| 46 | Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 337-341   | 1.6  | 5 |
| 45 | Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this?. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e88-e90   | 14.2 | 5 |
| 44 | A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 101-112  | 5.3  | 5 |
| 43 | The management of gout: Much has changed. <i>Australian Family Physician</i> , <b>2016</b> , 45, 299-302  |      | 5 |
| 42 | COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.. <i>Lancet Rheumatology, The</i> , <b>2022</b> ,  | 14.2 | 4 |
| 41 | Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: Comment on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Sby Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with            | 2.4  | 4 |
| 40 | Patients with gout: an under-recognised group at high risk of COVID-19. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e317-e318, <b>2020</b> ,   | 14.2 | 4 |
| 39 | Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine S | 2.4  | 4 |
| 38 | Severe hypothermia in association with sodium valproate overdose. <i>New Zealand Medical Journal</i> , <b>2005</b> , 118, U1681   | 0.8  | 4 |
| 37 | Top-Ten Tips for Imaging Groin Injury in Athletes. <i>Seminars in Musculoskeletal Radiology</i> , <b>2019</b> , 23, 361-375   | 1.5  | 3 |
| 36 | Biologic therapy for uveitis: addressing access issues is paramount. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 508-509   | 1.6  | 3 |
| 35 | Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study.. <i>Lancet Rheumatology, The</i> , <b>2022</b> ,   | 14.2 | 3 |
| 34 | A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 491-495  | 3.5  | 3 |
| 33 | Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4  | 3 |
| 32 | Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. <i>American Journal of Medicine</i> , <b>2021</b> ,  | 2.4  | 3 |

|    |   |      |   |
|----|---|------|---|
| 31 | COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , <b>2021</b> ,  | 4.1  | 3 |
| 30 | Does midlife obesity really lower dementia risk?. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 501   | 18.1 | 2 |
| 29 | Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1537-1543  | 4.7  | 2 |
| 28 | Inter- and intra-reader reproducibility of shear wave elastography measurements for musculoskeletal soft tissue masses. <i>Skeletal Radiology</i> , <b>2020</b> , 49, 779-786   | 2.7  | 2 |
| 27 | The effect of reducing systemic inflammation on serum urate. <i>Rheumatology</i> , <b>2020</b> , 59, 3108-3109  | 3.9  | 2 |
| 26 | Venous thromboembolism in medical inpatients--the silent epidemic of neglect. <i>Journal of the Royal Society of Medicine</i> , <b>2005</b> , 98, 484-5   | 2.3  | 2 |
| 25 | Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry   |      | 2 |
| 24 | Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. <i>PeerJ</i> , <b>2018</b> , 6, e5088  | 3.1  | 2 |
| 23 | Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 412-418        | 5.3  | 2 |
| 22 | Time to recognise gout as a chronic disease. <i>Medical Journal of Australia</i> , <b>2020</b> , 212, 285-285.e1  | 4    | 1 |
| 21 | Management of thyroid disease in pregnancy - Room for improvement in the first trimester. <i>Obstetric Medicine</i> , <b>2016</b> , 9, 126-9  | 1.5  | 1 |
| 20 | What does endemic COVID-19 mean for the future of rituximab?. <i>Lancet Rheumatology</i> , <b>2021</b> ,  | 14.2 | 1 |
| 19 | Gout, rheumatoid arthritis and the risk of death from COVID-19: an analysis of the UK Biobank   |      | 1 |
| 18 | Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 36  | 4.9  | 1 |
| 17 | Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 788-792     | 1.6  | 1 |
| 16 | Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab031 | 1.1  | 1 |
| 15 | The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 121-128   | 5.3  | 1 |
| 14 | The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 699-706  | 3.5  | 1 |



|    |   |      |   |
|----|---|------|---|
| 13 | SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.. <i>RMD Open</i> , <b>2022</b> , 8,   | 5.9  | 1 |
| 12 | Non-neoplastic Soft Tissue Tumors and Tumor-like Lesions. <i>Seminars in Musculoskeletal Radiology</i> , <b>2020</b> , 24, 645-666  | 1.8  | 0 |
| 11 | The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.. <i>Rheumatology Advances in Practice</i> , <b>2022</b> , 6, rkac001   | 1.1  | 0 |
| 10 | Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis.. <i>Rheumatology and Therapy</i> , <b>2021</b> , 9, 1  | 4.4  | 0 |
| 9  | Decreasing time to treatment in rheumatoid arthritis: review of delays in presentation, referral and assessment. <i>International Journal of Clinical Rheumatology</i> , <b>2011</b> , 6, 173-187   | 1.5  |   |
| 8  | Dr. Conway et al reply.. <i>Journal of Rheumatology</i> , <b>2022</b> , 49, 120-121   | 4.1  |   |
| 7  | Adherence to allopurinol in patients with gout: further insights generate further questions. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e249-e250   | 14.2 |   |
| 6  | Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Rosenbaum. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,             | 2.4  |   |
| 5  | Author reply. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 387  | 1.6  |   |
| 4  | Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , | 2.4  |   |
| 3  | Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. <i>BMC Rheumatology</i> , <b>2021</b> , 5, 33  | 2.9  |   |
| 2  | Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4  |   |
| 1  | Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1603-1616                          | 4.4  |   |